Literature DB >> 9463852

Modifying the design of ongoing trials without unblinding.

A L Gould1, W J Shih.   

Abstract

Conventional group sequential designs provide an objective basis for reducing the sample size of a trial if the difference between the treatments is much more or much less than anticipated. The flexibility of group sequential designs can be enhanced by allowing the sample size to increase when the variability turns out greater than expected. This can be accomplished by examining the variability before unblinding the data at the first stage of the trial. Depending on the result of this examination, the trial may continue as planned, or the design may change in various ways, for example, by increasing the sample size or by changing the number of stages or the scheduling of the interim analyses. The effect of this adaptive flexibility on the error rates turns out as one would expect from the findings for fixed-sample designs: no material impact on the type I error rate and an effect on the power that depends on the final total sample size.

Mesh:

Year:  1998        PMID: 9463852     DOI: 10.1002/(sici)1097-0258(19980115)17:1<89::aid-sim730>3.0.co;2-d

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Combining an Internal Pilot with an Interim Analysis for Single Degree of Freedom Tests.

Authors:  John A Kairalla; Keith E Muller; Christopher S Coffey
Journal:  Commun Stat Theory Methods       Date:  2010-12-01       Impact factor: 0.893

2.  Sample size re-estimation in a breast cancer trial.

Authors:  Erinn M Hade; David Jarjoura
Journal:  Clin Trials       Date:  2010-04-14       Impact factor: 2.486

3.  SCORE2 Report 2: Study Design and Baseline Characteristics.

Authors:  Ingrid U Scott; Paul C VanVeldhuisen; Michael S Ip; Barbara A Blodi; Neal L Oden; Maria Figueroa; Pravin U Dugel
Journal:  Ophthalmology       Date:  2016-11-15       Impact factor: 12.079

4.  Distribution Theory Following Blinded and Unblinded Sample Size Re-estimation under Parametric Models.

Authors:  Sergey Tarima; Nancy Flournoy
Journal:  Commun Stat Simul Comput       Date:  2019-11-22       Impact factor: 1.162

5.  The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke.

Authors:  Askiel Bruno; Valerie L Durkalski; Christiana E Hall; Rattan Juneja; William G Barsan; Scott Janis; William J Meurer; Amy Fansler; Karen C Johnston
Journal:  Int J Stroke       Date:  2013-03-19       Impact factor: 5.266

6.  The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial: an adaptive trial design case study.

Authors:  Jason T Connor; Kristine R Broglio; Valerie Durkalski; William J Meurer; Karen C Johnston
Journal:  Trials       Date:  2015-03-04       Impact factor: 2.279

7.  A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials.

Authors:  J Bowden; A Mander
Journal:  Pharm Stat       Date:  2014-04-02       Impact factor: 1.894

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.